Alexis, A. F. .; Merola, J. F. .; Zhong, Y. .; Zhuo, J. .; Becker, B. .; Napoli, A. .; Ross, J. .; Beaumont, J. .; DeRosa, M. .; Banerjee, S. .; Armstrong, A. W. . Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in the Phase 3 Clinical Trials in Psoriasis, POETYK PSO-1 and PSO-2: Time to Meaningful Improvements in Itch As Assessed by the Psoriasis Symptoms and Signs Diary. J of Skin 2024, 8, s358.